Cardio Diagnostics Holdings (CDIO) Capital Expenditures (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Capital Expenditures of $1760.0 for Q1 2026, down 98.92% sequentially from $162834.0 in Q3 2025, and down 69.59% YoY from $5787.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Capital Expenditures (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Capital Expenditures for 5 years, with the latest figure at $1760.0 in Q1 2026.
- Quarterly Capital Expenditures fell 69.59% year-over-year to $1760.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183290.0 (down 8.61% YoY) and the FY2025 annual result came in at $187317.0, down 12.78% from the prior year.
- Capital Expenditures declined to $1760.0 in Q1 2026 per CDIO's latest filing, from $162834.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $537053.0 in Q4 2023 and troughed at -$256991.0 in Q2 2023.
- A 5-year average of $89859.9 and a median of $19985.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures plunged 99.32% in 2024, then soared 600.48% in 2025.
- Over 5 years, Capital Expenditures stood at $188674.0 in 2022, then jumped by 184.65% to $537053.0 in 2023, then slumped by 99.32% to $3638.0 in 2024, then jumped by 4375.92% to $162834.0 in 2025, then plunged by 98.92% to $1760.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $1760.0, $162834.0, and $18696.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 251.02 Mn |
| 10 | Cardio Diagnostics Holdings | 6.13 Mn | 539,403.63 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,760.00 |
| Mar 31, 2026 | 1,760.00 |
| Sep 30, 2025 | 162,834.00 |
| Sep 30, 2025 | 162,834.00 |
| Jun 30, 2025 | 18,696.00 |
| Jun 30, 2025 | 18,696.00 |
| Mar 31, 2025 | 5,787.00 |
| Mar 31, 2025 | 5,787.00 |
| Dec 31, 2024 | 3,638.00 |
| Dec 31, 2024 | 3,638.00 |
| Sep 30, 2024 | 23,246.00 |
| Sep 30, 2024 | 23,246.00 |
| Jun 30, 2024 | 167,896.00 |
| Jun 30, 2024 | 167,896.00 |
| Mar 31, 2024 | 19,985.00 |
| Mar 31, 2024 | 19,985.00 |
| Dec 31, 2023 | 537,053.00 |
| Dec 31, 2023 | 537,053.00 |
| Sep 30, 2023 | 12,591.00 |
| Sep 30, 2023 | 12,591.00 |